Sigrid P. Dubois, Ph.D.
Staff Scientist

Center for Cancer Research
National Cancer Institute

Building 10 - Magnuson CC, Room 4N109
Bethesda, MD 20892-1374
301-435-4441

One of the Dr. Dubois' major contributions has been the characterization of the mechanism of action of IL-15. Instead of acting as a soluble factor, IL-15Ralpha retains IL-15 via a high-affinity interaction on the cell surface and trans-presents it to neighboring NK and CD8+ T cells that express IL-2/15Rbeta and gammac. Studies conducted by Dr. Dubois have helped in understanding the regulation of IL-15 production and its role in the development of some CD8 populations as well as its contribution to the activation/proliferation of NK cells. Dr. Dubois has been involved in the use of IL-15 in the treatment of malignancies in mice, where it has been found to be effective. Ultimately, the work of Dr. Dubois contributed to the GMP production of IL-15 that has been used in a first-in-human clinical trial as a new therapy for patients with metastatic malignant melanoma and renal cell cancer. Currently, two main projects conducted by Dr. Dubois focus on: 1) the role of IL-15 in the development of T cell malignancy, and 2) the development of a new therapy supporting the anti-tumor activity of NK cells.

Areas of Expertise
IL-15

The main focus of the laboratory of Dr. Thomas A. Waldmann is the role of Interleukin-2 (IL-2) and IL-15 on the regulation of human immune responses. One of the Dr. Dubois' major contributions has been the characterization of the mechanism of action of IL-15. Instead of acting as a soluble factor, IL-15Ralpha retains IL-15 via a high-affinity interaction on the cell surface and trans-presents it to neighboring NK and CD8+ T cells that express IL-2/15Rbeta and gammac. Studies conducted by Dr. Dubois have helped in understanding the regulation of IL-15 production and its role in the development of some CD8 populations as well as its contribution to the activation/proliferation of NK cells. Dr. Dubois has been involved in the use of IL-15 in the treatment of malignancies in mice, where it has been found to be effective. Ultimately, the work of Dr. Dubois contributed to the GMP production of IL-15 that has been used in a first-in-human clinical trial as a new therapy for patients with metastatic malignant melanoma and renal cell cancer. Currently, two main projects conducted by Dr. Dubois focus on: 1) the role of IL-15 in the development of T cell malignancy, and 2) the development of a new therapy supporting the anti-tumor activity of NK cells.

Selected Publications
  1. Dubois S, Patel HJ, Zhang M, Waldmann TA, Müller JR.
    J. Immunol.. 180: 2099-106, 2008. [ Journal Article ]
  2. Dubois S, Mariner J, Waldmann TA, Tagaya Y.
    Immunity. 17: 537-47, 2002. [ Journal Article ]
  3. Müller JR, Waldmann TA, Kruhlak MJ, Dubois S.
    J. Biol. Chem.. 287: 40328-38, 2012. [ Journal Article ]
  4. Müller JR, Waldmann TA, Dubois S.
    J. Immunol.. 188: 2575-82, 2012. [ Journal Article ]
  5. Zhang M, Yao Z, Dubois S, Ju W, Müller JR, Waldmann TA.
    Proc. Natl. Acad. Sci. U.S.A.. 106: 7513-8, 2009. [ Journal Article ]

Dr. Sigrid Dubois earned her Ph.D. degree in 1999 from the University of Sciences of Nantes, France. She obtained postdoctoral training in the NCI Lymphoid Malignancies Branch (formerly, Metabolism Branch) where she now serves as a staff scientist in the laboratory of Dr. Thomas A. Waldmann.

Summary

One of the Dr. Dubois' major contributions has been the characterization of the mechanism of action of IL-15. Instead of acting as a soluble factor, IL-15Ralpha retains IL-15 via a high-affinity interaction on the cell surface and trans-presents it to neighboring NK and CD8+ T cells that express IL-2/15Rbeta and gammac. Studies conducted by Dr. Dubois have helped in understanding the regulation of IL-15 production and its role in the development of some CD8 populations as well as its contribution to the activation/proliferation of NK cells. Dr. Dubois has been involved in the use of IL-15 in the treatment of malignancies in mice, where it has been found to be effective. Ultimately, the work of Dr. Dubois contributed to the GMP production of IL-15 that has been used in a first-in-human clinical trial as a new therapy for patients with metastatic malignant melanoma and renal cell cancer. Currently, two main projects conducted by Dr. Dubois focus on: 1) the role of IL-15 in the development of T cell malignancy, and 2) the development of a new therapy supporting the anti-tumor activity of NK cells.

Areas of Expertise
IL-15

Research

The main focus of the laboratory of Dr. Thomas A. Waldmann is the role of Interleukin-2 (IL-2) and IL-15 on the regulation of human immune responses. One of the Dr. Dubois' major contributions has been the characterization of the mechanism of action of IL-15. Instead of acting as a soluble factor, IL-15Ralpha retains IL-15 via a high-affinity interaction on the cell surface and trans-presents it to neighboring NK and CD8+ T cells that express IL-2/15Rbeta and gammac. Studies conducted by Dr. Dubois have helped in understanding the regulation of IL-15 production and its role in the development of some CD8 populations as well as its contribution to the activation/proliferation of NK cells. Dr. Dubois has been involved in the use of IL-15 in the treatment of malignancies in mice, where it has been found to be effective. Ultimately, the work of Dr. Dubois contributed to the GMP production of IL-15 that has been used in a first-in-human clinical trial as a new therapy for patients with metastatic malignant melanoma and renal cell cancer. Currently, two main projects conducted by Dr. Dubois focus on: 1) the role of IL-15 in the development of T cell malignancy, and 2) the development of a new therapy supporting the anti-tumor activity of NK cells.

Publications

Selected Publications
  1. Dubois S, Patel HJ, Zhang M, Waldmann TA, Müller JR.
    J. Immunol.. 180: 2099-106, 2008. [ Journal Article ]
  2. Dubois S, Mariner J, Waldmann TA, Tagaya Y.
    Immunity. 17: 537-47, 2002. [ Journal Article ]
  3. Müller JR, Waldmann TA, Kruhlak MJ, Dubois S.
    J. Biol. Chem.. 287: 40328-38, 2012. [ Journal Article ]
  4. Müller JR, Waldmann TA, Dubois S.
    J. Immunol.. 188: 2575-82, 2012. [ Journal Article ]
  5. Zhang M, Yao Z, Dubois S, Ju W, Müller JR, Waldmann TA.
    Proc. Natl. Acad. Sci. U.S.A.. 106: 7513-8, 2009. [ Journal Article ]

Biography

Dr. Sigrid Dubois earned her Ph.D. degree in 1999 from the University of Sciences of Nantes, France. She obtained postdoctoral training in the NCI Lymphoid Malignancies Branch (formerly, Metabolism Branch) where she now serves as a staff scientist in the laboratory of Dr. Thomas A. Waldmann.